BRAF inhibitors can enhance the expression of major histocompatibility complex (MHC) class I and class II molecules and, melanocyte differentiation antigen (MDA), while reducing PD-L1 and suppressor cells (Treg/Myeloid-Derived Suppressor Cells), reshaping the tumor microenvironment and promoting CD8+ T cell infiltration and activation. Here, CD274 is linked to neoplasm.